Resumo
Objetivo: Sintetizar criticamente as evidências recentes sobre hiponatremia em contexto hospitalar, considerando fundamentos fisiopatológicos, critérios clínicos‑laboratoriais, estratégias de correção, incluindo solução salina hipertônica, e repercussões clínicas, funcionais e assistenciais sob perspectiva multiprofissional. Métodos: Revisão integrativa com busca ampliada em nove bases (2021–2026), contemplando um núcleo analítico (ensaio clínico, estudos observacionais e revisões sistemáticas/metanálises) e um suporte contextual (diretrizes e revisões narrativas/práticas) integrados à interpretação crítica dos achados. Após triagem de 1.482 registros e avaliação de 75 textos completos, 12 estudos compuseram a síntese final. Resultados: Em hiponatremia grave, a correção rápida controlada associou‑se a melhores desfechos clínicos quando conduzida com monitorização rigorosa. Em quadros sintomáticos, bolus de solução salina hipertônica demonstrou maior eficiência operacional que infusões contínuas. Hiponatremia leve/moderada mostrou associação consistente com instabilidade postural e quedas, embora os efeitos sobre fraturas permaneçam incertos. Identificaram‑se ainda prolongamento do tempo de internação, maior risco de readmissões e implicações organizacionais relevantes. Considerações finais: O manejo hospitalar da hiponatremia requer metas paramétricas claras, monitorização seriada e integração multiprofissional. Persistem lacunas terapêuticas e funcionais que justificam novas investigações.
Referências
ADROGUÉ HJ, et al. Diagnosis and management of hyponatremia. JAMA, 2022; 328(3): 280–291.
AMERICAN ACADEMY OF HOSPICE AND PALLIATIVE MEDICINE. Clinical Practice Guidelines for Quality Palliative Care. 5. ed. Chicago: AAHPM, 2022.
AYUS JC, et al. Correction rates and clinical outcomes in hospitalized adults with severe hypo-natremia: a systematic review and meta-analysis. JAMA Internal Medicine, 2025; 185(1): 38–51.
BAEK SH, et al. Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion of hyper-tonic saline in symptomatic hyponatremia (SALSA). JAMA Internal Medicine, 2021; 181(1): 81–92.
CHRIST CRAIN M, et al. Approach to the patient: utility of the copeptin assay. Journal of Clinical En-docrinology & Metabolism, 2022; 107(6): 1727–1738.
FRATANGELO L, et al. Hyponatremia and aging-related diseases: key player or innocent bystander? A systematic review. Systematic Reviews, 2023; 12: 84.
KUTZ A, et al. Risk of adverse clinical outcomes in hyponatremic adult medical inpatients: a popula-tion-based cohort study. Journal of Clinical Endocrinology & Metabolism, 2020; 105(11): 3428–3436.
LU H, et al. Prevalence and description of hyponatremia in a Swiss tertiary care hospital: an observa-tional retrospective study. Frontiers in Medicine, 2020; 7: 512.
MONNERAT S, et al. Hyponatraemia in ageing. Nature Reviews Endocrinology, 2025; 21: ePub ahead of print.
PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 372: n71.
POTASSO L, et al. Impact of hyponatremia on bone, a narrative review. European Journal of Endocri-nology, 2025; 193(6): R89–R97.
RAJENDRAM R, et al. Associations between day of admission, admission hyponatremia and hospital outcomes in medical patients: a retrospective multicenter cohort study. PLOS ONE, 2025; 20(10): e0335248.
RENNEBOOG B, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. American Journal of Medicine, 2006; 119(1): 71.e1–71.e8.
REFARDT J, et al. Hyponatremia Intervention Trial (HIT): study protocol of a randomized, controlled, parallel group trial with blinded outcome assessment. Frontiers in Medicine, 2021; 8: 729545.
ROE T, et al. Intensive care management of severe hyponatraemia—an observational study. Medicina, 2024; 60(9): 1412.
SEETHAPATHY H, et al. Severe hyponatremia correction, mortality, and central pontine myelinolysis. NEJM Evidence, 2023; 2(10): EVIDoa2300107.
SHEA BJ, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017; 358: j4008.
SPASOVSKI G. Hyponatraemia—treatment standard 2024. Nephrology Dialysis Transplantation, 2024; 39(10): 1583–1592.
SPASOVSKI G, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Europe-an Journal of Endocrinology, 2014; 170(3): G1–G47.
STERNE JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019; 366: l4898.
STERNE JAC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interven-tions. BMJ, 2016; 355: i4919.
TZOULIS P, YAVROPOULOU MP. Association of hyponatremia with bone mineral density and frac-tures: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 2023; 14: 20420188231197921.
WARREN AM, et al. Syndrome of inappropriate antidiuresis: from pathophysiology to management. Endocrine Reviews, 2023; 44(5): 819–861.
LIVROS
HIGGINS JPT, THOMAS J, CHANDLER J, et al. Cochrane Handbook for Systematic Reviews of Inter-ventions. Versão 6.5. Cochrane: Londres UK, 2024.
